Abstract
<h3>Background</h3> Invasive yeast infections are an important clinical problem. The incidence of a non-<i>albicans Candida</i> species has been increasing and several non-<i>albicans</i> species have reduced susceptibility to azole agents. Significant work has been undertaken to improve antifungal susceptibility testing and susceptibility results help predict those isolates more likely to respond to therapy. Encouraging moves are being made to align Clinical and Laboratory Standards Institute (CLSI) and EUCAST interpretative criteria. <h3>Methods</h3> The new CLSI interpretation criteria for fluconazole, caspofungin and voriconazole will be discussed. <h3>Results</h3> The impact of the new CLSI criteria on the interpretation of more than 1400 New Zealand yeast isolates will be presented. Recent susceptibility results from the Royal College of Patholo-gists of Australasia (RCPA) Microbiology Quality Assurance Program (QAP) will also be discussed. <h3>Conclusion</h3> Although more data are required for some agents and organism pairings the use of molecular methods, pharmacodynam-ic information, epidemiological cut-off values, and clinical data will continue to improve the interpretation of yeast susceptibility results.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
